ライフサイエンスコーパス: sertraline

1 ential (fluoxetine, fluvoxamine, paroxetine, sertraline).

2 fluoxetine and improved remission more than sertraline.

3 had fewer side effects with escitalopram and sertraline.

4 ioning with CBT-ip for PNES without and with sertraline.

5 een in the patients showing poor response to sertraline.

6 weeks of open-label treatment with the SSRI sertraline.

7 nction reduces the affinity of membranes for sertraline.

8 elective serotonin reuptake inhibitor (SSRI) sertraline.

9 with positive response to bupropion but not sertraline.

10 acceptability in favour of escitalopram and sertraline.

11 with cognitive behavioral therapy than with sertraline.

12 ere then randomized to prolonged exposure or sertraline.

13 ic compounds for MEGF10 myopathy, especially sertraline.

14 All participants continued sertraline.

15 depression (p < 0.0001) but not seizures or sertraline.

16 days before treatment diminished over time (sertraline, -0.7 [3.4] days; placebo, -1.0 [3.2] days),

17 Interventions: Placebo or sertraline, 100 mg/d, for 24 weeks or until development

18 placebo) and the end point (15.3 [10.7] for sertraline; 17.8 [11.0] for placebo) favored the sertral

19 7 participants received at least one dose of sertraline; 181 nonresponders (LSAS score >50) at week 1

20 signed to receive 14 weeks of treatment with sertraline (200 mg/day [N=40]), naltrexone (100 mg/day [

21 cant for both the CBT (25.7%; p < 0.001) and sertraline (28.3%; p < 0.001) groups.

22 S-C scores between baseline (35.4 [10.7] for sertraline; 32.8 [10.4] for placebo) and the end point (

23 Patients received one capsule (sertraline 50 mg or placebo orally) daily for one week t

24 d, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day versus matching placebo for

25 4 months of aerobic exercise (3 times/week), sertraline (50-200 mg/day), or placebo.

26 Whether higher doses of omega-3 or sertraline, a different ratio of EPA to DHA, longer trea

27 nvestigated the transgenerational effects of sertraline, a selective serotonin reuptake inhibitor, an

28 one (abstinence rate: 21.3%; delay=29 days), sertraline (abstinence rate: 27.5%; delay=23 days), and

29 when comparing the combined treatment group (sertraline/active tDCS) vs sertraline only (mean differe

30 Acute sertraline administration can modulate P-gp activity in

31 The Sertraline Against Depression and Heart Disease in Chron

32 The SADHART-CHF (Sertraline Against Depression and Heart Disease in Chron

33 e [LSAS] score >50) after a 10-week trial of sertraline alone: the addition of up to 3.0 mg/day of cl

34 Sertraline also restored deficiencies of Notch1 in disea

35 likelihood of substantially benefiting from sertraline among patients with SAD.

36 ed drug screen, we identified the ability of sertraline (an antidepressant) to block the formation of

37 elated neural activity moderated response to sertraline, an antidepressant medication that targets th

38 randomly assigned 655 patients-326 (50%) to sertraline and 329 (50%) to placebo.

39 [CI] = +/-12) of the 72 subjects assigned to sertraline and 41 (60.3%; 95% CI = +/-11.6) of the 68 su

40 to treatment (77 of 115 patients [67.0%] for sertraline and 65 of 124 [52.4%] for placebo; chi21 = 5.

41 The combination of sertraline and CBT significantly reduced clinician-repor

42 e evaluated the comparative effectiveness of sertraline and cognitive behavior therapy (CBT) for depr

43 onin), psychiatric hospitalization rate (for sertraline and escitalopram), and insulin initiation (fo

44 ctive serotonin reuptake inhibitors (SSRIs), sertraline and escitalopram.

45 es for CSM-contraindicated SSRIs citalopram, sertraline and especially paroxetine dropped dramaticall

46 f two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.

47 Sertraline and norsertraline were the most abundant anti

48 patients with CHD and major depression with sertraline and omega-3 fatty acids did not result in sup

49 fferentially predicted) outcomes between the sertraline and placebo arms.

50 oups, while change from baseline between the sertraline and placebo groups was significantly differen

51 d, and adverse effects were mild in both the sertraline and placebo groups.

52 e of the same intervention in stage 2, while sertraline and placebo nonresponders crossed over to bup

53 pression outcomes at 10 weeks, compared with sertraline and placebo.

54 n period, all patients were given 50 mg/d of sertraline and randomized in double-blind fashion to rec

55 rotonin reuptake inhibitors escitalopram and sertraline and the serotonin-norepinephrine reuptake inh

56 We recorded seven adverse events-four for sertraline and three for placebo, and adverse events did

57 mporal gyrus was associated with response to sertraline and venlafaxine, but not escitalopram.

58 95% CI, 0.59 to 1.93) or between the use of sertraline and ventricular septal defects (relative risk

59 n Rating Scale total score was -7.1 +/- 0.5 (sertraline) and -6.8 +/- 0.5 (placebo) (p < 0.001 from b

60 mbining approved medications for depression (sertraline) and alcohol dependence (naltrexone) in treat

61 rticipants, 125 with PMDD were randomized to sertraline, and 127 to placebo.

62 behavioral therapy, which was equivalent to sertraline, and all therapies were superior to placebo.

63 commonly used antidepressants (escitalopram, sertraline, and extended-release venlafaxine), using mul

64 ese drugs, including imipramine, citalopram, sertraline, and fluoxetine (Prozac), bound more avidly t

65 pproaches included the use of nortriptyline, sertraline, and omega-3 fatty acids.

66 P)-bearing pseudoviruses; three (clomiphene, sertraline, and toremifene) were more potent against EBO

67 pine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine.

68 cipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine.

69 We observed the participants of the Sertraline Antidepressant Heart Attack Randomized Trial

70 Conclusions and Relevance: Sertraline appears to be efficacious to prevent the onse

71 We selected sertraline as a model SSRI for a 28-d study with adult m

72 ining citalopram, loperamide, methadone, and sertraline as model substances were spotted on alginate

73 k predicted better outcomes specifically for sertraline, as did greater between-network connectivity

74 nce that depressive symptoms were reduced by sertraline at 12 weeks.

75 rticipants were randomly assigned to receive sertraline at 200 mg (n=48), 300 mg (n=36), or 400 mg (n

76 vity changes at 1 week predicted response to sertraline at 8 weeks.

77 bility, the first 60 participants were given sertraline at escalating doses of 100 mg/day, 200 mg/day

78 andomly assigned (1:1) to receive open-label sertraline at predetermined doses of 200 mg/day, 300 mg/

79 For sertraline, attenuation of connectivity in the precentra

80 was increased 5 minutes after treatment with sertraline, but by 60 minutes after sertraline treatment

81 Ingestion of sertraline by females did not affect their fecundity or

82 ural product (-)-nicotine and antidepressant sertraline by late-stage amination and azidation reactio

83 The sertraline cohort revealed similar findings, except ther

84 The lithium/sertraline combination group had a significantly higher

85 therapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with simi

86 The dropout rate was higher in the lithium/sertraline combination treatment group, without any trea

87 However, treatment with sertraline compared with placebo did not provide greater

88 alysis-dependent CKD and MDD, treatment with sertraline compared with placebo for 12 weeks did not si

89 ential outcome to antidepressant medication (sertraline) compared with placebo.

90 ed with insufficient duration of therapeutic sertraline concentrations.

91 Prolonged exposure and sertraline confer significant benefits for PTSD, with so

92 , double-dummy, parallel-group, placebo- and sertraline-controlled trial.

93 0 mg of CP-316,311 twice daily, or 100 mg of sertraline daily, or placebo in a 6-week fixed-dose, dou

94 nts paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot flash scores by 41%, 33%, 13%,

95 The efficacy and safety of tDCS and sertraline did not differ.

96 Sertraline did not reduce mortality and should not be us

97 r demonstrate that the SSRIs, fluoxetine and sertraline, directly suppress TIDA neuron activity throu

98 Participants receiving any sertraline dose averaged a CSF clearance rate of -0.37 c

99 have suggested that children of women taking sertraline during pregnancy have an increased risk of de

100 Fish plasma levels of sertraline exceeding human therapeutic doses were accura

101 However, larvae that consumed sertraline experienced delayed developmental progression

102 ted in mammals and fish models to respond to sertraline exposure, was selected as an endpoint associa

103 Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were

104 tial effectiveness of prolonged exposure and sertraline for the treatment of posttraumatic stress dis

105 9 of 111 [26%]) than did participants in the sertraline group (46 of 107, 43%; p=0.010) or mirtazapin

106 aseline QIDS-C16 score was 14.0 (2.4) in the sertraline group (n = 97) and 14.1 (2.4) in the placebo

107 t 18 weeks, 120 (52%) of 229 patients in the sertraline group and 106 (46%) of 231 patients in the pl

108 me analyses were of 550 patients (266 in the sertraline group and 284 in the placebo group; 85% follo

109 9.9%, 40.6%, and 29.5%, respectively, in the sertraline group and 31.1%, 43.8%, and 25.1%, respective

110 6-week PHQ-9 score was 7.98 (SD 5.63) in the sertraline group and 8.76 (5.86) in the placebo group (a

111 The QIDS-C16 score changed by -4.1 in the sertraline group and by -4.2 in the placebo group (betwe

112 events were classified as serious-two in the sertraline group and one in the placebo group.

113 Three patients in the sertraline group and three patients in the placebo group

114 raline; 17.8 [11.0] for placebo) favored the sertraline group by 5.14 (95% CI, 1.97-8.31) points (P =

115 Two patients in the sertraline group did not complete a substantial proporti

116 cidal ideation, were no more frequent in the sertraline group than in the placebo group.

117 ality of Life Survey (median score, 0 in the sertraline group vs 0 in the placebo group; between-grou

118 10) CFU/mL per day [95% CI 0.37-0.50] in the sertraline group vs 0.47 -log(10) CFU/mL per day [0.40-0

119 One serious adverse event in the sertraline group was classified as possibly related to s

120 in the placebo group, and 30 patients in the sertraline group.

121 between participants in the mirtazapine and sertraline groups (1.16, -0.25 to 2.57; p=0.11); these f

122 1 mumol/L and 10 mumol/L; order of potency: sertraline > fluoxetine > paroxetine > fluvoxamine > cit

123 maller percentage of participants prescribed sertraline had a depression recurrence compared with tho

124 Participants receiving sertraline had faster cryptococcal CSF clearance and a l

125 Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytr

126 Sertraline has previously shown in vitro and in vivo act

127 o brand-name initiation for escitalopram and sertraline (HR [95% CI]: 1.06 [0.98-1.13] and 1.11 [1.05

128 plus 2 extra sessions every other week) and sertraline hydrochloride (50 mg/d).

129 Sertraline hydrochloride is a commonly prescribed antide

130 Sertraline hydrochloride was reported to have anti-Ebola

131 Sertraline hydrochloride was started at 50 mg/d and incr

132 Medication (flexible-dose sertraline hydrochloride) only, cognitive behavioral the

133 Placebo or sertraline hydrochloride, 50 to 100 mg/d, during the sym

134 02 (95% confidence interval, 0.77-1.35); and sertraline hydrochloride, hazard ratio = 0.75 (95% confi

135 ydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride.

136 h the selective serotonin reuptake inhibitor sertraline hydrochloride.

137 udies on warfarin, ibuprofen, furosemide and sertraline implied that our method was able to rank poss

138 To determine whether treatment with sertraline improves depressive symptoms in patients with

139 fficacy and cost-effectiveness of adjunctive sertraline in adults with HIV-associated cryptococcal me

140 depressed individuals were then treated with sertraline in an open-label manner for 8 weeks, and PBMC

141 e investigated the clinical effectiveness of sertraline in patients in primary care with depressive s

142 with major depressive disorder treated with sertraline in stage 1 served as an independent replicati

143 The influence of sertraline in the course of neuropsychological variables

144 ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of a list of compounds ranked

145 SRIs: citalopram, paroxetine, fluoxetine and sertraline) in a retrospective cohort mainly consisting

146 The reasons for sertraline inactivity appear to be multifactorial and mi

147 A combination of 11 with the SSRI sertraline increased the anorectic effect.

148 Sertraline increased the F0-daphnid fecundity whereas it

149 In MDD, the combination of tDCS and sertraline increases the efficacy of each treatment.

150 may have implications for the biomedicine of sertraline-induced birth defects.

151 Remarkably, the sertraline-induced genotoxicity was partially rescued by

152 cubation with ascorbic acid, suggesting that sertraline induces oxidative DNA damage.

153 ne with the SSRIs paroxetine, fluoxetine, or sertraline inhibited insulin-induced Tyr phosphorylation

154 ted enzyme assays, we also demonstrated that sertraline inhibits phospholipase A(1) and phospholipase

155 f vacuolar ATPase activity reduces uptake of sertraline into cells, whereas dysregulation of clathrin

156 Prediction of response to sertraline involved several within- and between-network

157 Sertraline is unlikely to reduce depressive symptoms wit

158 We found no evidence that sertraline led to a clinically meaningful reduction in d

159 r secondary outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better menta

160 ; 95% confidence interval: -9.8 to -5.0) and sertraline (mean -6.1; 95% confidence interval: -8.4 to

161 ls and 107 participants allocated to receive sertraline (mean difference 1.17, 95% CI -0.23 to 2.58;

162 Sertraline might be the best choice when starting treatm

163 igned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment

164 ing strategy, we demonstrated that high dose sertraline monotherapy provided no benefit for the preve

165 Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combinati

166 cebo run-in, participants were randomized to sertraline (n = 102) for 12 weeks at an initial dose of

167 icated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establi

168 tpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blin

169 escription for citalopram (N=618,450) or for sertraline (N=365,898), a comparison medication with no

170 ), or combination treatment with lithium and sertraline (N=48).

171 tal of 469 patients were randomized (n = 234 sertraline, n = 235 placebo).

172 tion strategy provides relative benefits for sertraline nonresponders in social anxiety disorder.

173 associated with response to bupropion after sertraline nonresponse.

174 s were observed for a comparison medication, sertraline, not subject to the FDA warning.

175 Patients preferred prolonged exposure over sertraline (number needed to benefit [NNTB]=4.5).

176 and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84%) completed the study.

177 gnificant benefit of prolonged exposure over sertraline on interview-rated loss of PTSD diagnosis (NN

178 For example, naphthalene was converted into sertraline, one of the most prescribed antidepressants,

179 treatment group (sertraline/active tDCS) vs sertraline only (mean difference, 8.5 points; 95% CI, 2.

180 Analysis of tDCS only vs sertraline only presented comparable efficacies (mean di

181 Use of tDCS only (but not sertraline only) was superior to placebo/sham tDCS.

182 The sertraline-only arm did not show a reduction in seizures

183 There were no improvements in the sertraline-only or treatment-as-usual arms.

184 in just over one-half of subjects following sertraline or CBT.

185 elective serotonin reuptake inhibitor (SSRI) sertraline or cognitive behavior therapy (CBT), particip

186 e disorder patients randomized to 8 weeks of sertraline or placebo (Cohort D, n = 200).

187 e substantially during treatment with either sertraline or placebo (hazard ratio, 2.39; 95% confidenc

188 5 to 20 mg of olanzapine per day plus masked sertraline or placebo at 150 to 200 mg per day.

189 Statistics Manual fourth edition criteria to sertraline or placebo for 12 weeks.

190 ipants were randomized to receive 8 weeks of sertraline or placebo in stage 1.

191 ere then randomly assigned to receive either sertraline or placebo treatment for 8 weeks (N=279).

192 :1) with a remote computer-generated code to sertraline or placebo, and were stratified by severity,

193 arting at 800 mg/day) with either adjunctive sertraline or placebo.

194 zed open-label treatment ADMs: escitalopram, sertraline or venlafaxine-extended release.

195 Patients were randomized to escitalopram, sertraline or venlafaxine-XR antidepressants and assesse

196 psy and current major depressive disorder to sertraline or weekly CBT for 16 weeks.

197 erapy (CBT-ip) only, CBT-ip with medication (sertraline), or treatment as usual.

198 eted 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine (all substra

199 d to 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine.

200 n = 124) randomized to receive escitalopram, sertraline, or venlafaxine (8 weeks) and healthy control

201 of three antidepressant drugs (escitalopram, sertraline, or venlafaxine extended-release).

202 ipants were then randomized to escitalopram, sertraline, or venlafaxine-extended release, and were as

203 In contrast, both placebo and sertraline outcomes were predicted (in opposite directio

204 conflict-responsive regions predicted better sertraline outcomes.

205 italopram was associated with intolerance to sertraline (P = .04).

206 ents in heart rate variability compared with sertraline (p = 0.093).

207 behavioral therapy (P<0.001), and 54.9% for sertraline (P<0.001); all therapies were superior to pla

208 randomized using a 2 x 2 factorial design to sertraline/placebo and active/sham tDCS.

209 he endpoint, and 27% of patients assigned to sertraline plus clonazepam achieved remission compared w

210 cantly greater proportion of patients in the sertraline plus clonazepam group (56%) compared with the

211 Sertraline plus clonazepam was associated with a signifi

212 addition of up to 3.0 mg/day of clonazepam (sertraline plus clonazepam), a switch to up to 225 mg/da

213 re >50) at week 10 were randomly assigned to sertraline plus clonazepam, switch to venlafaxine, or se

214 faxine and either sertraline plus placebo or sertraline plus clonazepam.

215 n venlafaxine and sertraline plus placebo or sertraline plus clonazepam.

216 xone (100 mg/day [N=49]), the combination of sertraline plus naltrexone (N=42), or double placebo (N=

217 sed alcohol-dependent patients receiving the sertraline plus naltrexone combination achieved abstinen

218 The sertraline plus naltrexone combination produced a higher

219 sychotic depression in remission, continuing sertraline plus olanzapine compared with sertraline plus

220 of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks and met cr

221 remission compared with patients assigned to sertraline plus placebo (17%) or venlafaxine (19%), but

222 lus clonazepam group (56%) compared with the sertraline plus placebo group responding (36%; p=0.027);

223 se parameters between venlafaxine and either sertraline plus placebo or sertraline plus clonazepam.

224 t reach significance between venlafaxine and sertraline plus placebo or sertraline plus clonazepam.

225 ing sertraline plus olanzapine compared with sertraline plus placebo reduced the risk of relapse over

226 prolonged sertraline treatment with placebo (sertraline plus placebo).

227 e plus clonazepam, switch to venlafaxine, or sertraline plus placebo.

228 020) and disability (p=0.0028) compared with sertraline plus placebo; no significant differences were

229 This sertraline-predictive EEG signature generalized to two d

230 y and microbiological efficacy of adjunctive sertraline, previously shown to have in-vitro and in-viv

231 nonresponders crossed over to bupropion and sertraline, respectively.

232 L for citalopram, loperamide, methadone, and sertraline, respectively.

233 Sertraline responders had higher functional connectivity

234 Furthermore, we found that the sertraline resting-state EEG signature indexed prefronta

235 Both exercise and sertraline resulted in greater reductions in depressive

236 In vitro, sertraline resulted in rapid and potent inhibition of P-

237 rolonged treatment (16 h) of Min6 cells with sertraline resulted in the induction of inducible nitric

238 nd clathrin-coat formation--as modulators of sertraline's action at membranes.

239 ere randomized to 1 of 3 arms: escitalopram, sertraline (serotonin-specific reuptake inhibitors [SSRI

240 ed with the placebo group, those assigned to sertraline showed greater improvement on the total DRSP

241 nalyses (N=200), both prolonged exposure and sertraline showed large gains that were maintained over

242 Escitalopram and sertraline showed the best profile of acceptability, lea

243 The combined arm (CBT-ip with sertraline) showed 59.3% seizure reduction (P = .008) an

244 Remarkably, sublethal doses of sertraline stimulate growth of mutants with impaired cla

245 pressant trial (level 1), either a switch to sertraline, sustained-release bupropion, or extended-rel

246 ing block sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45

247 the absence of its putative protein target, sertraline targets phospholipid membranes that comprise

248 rotonin reuptake inhibitors escitalopram and sertraline than did A allele carriers.

249 The response rate was slightly higher for sertraline than for placebo (21/35 [60%] vs. 20/40 [50%]

250 cits, was associated with better response to sertraline than placebo.

251 Adverse events were more frequent in the sertraline than the CBT group.

252 treatment compared with 60% after short-term sertraline therapy, with a median time to relapse of 8 m

253 gaster model system to assess the effects of sertraline throughout development.

254 We gave 100 mg/day sertraline to 17 patients, 200 mg/day to 12 patients, 30

255 xin), was co-administered with fluoxetine or sertraline to determine if either compound increased dru

256 These findings do not support the use of sertraline to treat MDD in patients with non-dialysis-de

257 Ultrastructural studies of sertraline-treated cells revealed a phenotype that resem

258 re system, we showed that mitotically active sertraline-treated tissues accumulate DNA double-strand

259 BT delivered in the dialysis facility versus sertraline treatment (phase 2).

260 By 240 minutes after sertraline treatment brain digoxin accumulation was elev

261 Moreover, inactivation of TCTP by sertraline treatment enhances UVC irradiation-induced ap

262 Objective: To assess the efficacy of sertraline treatment in preventing depressive disorders

263 Compared with CBT, sertraline treatment resulted in lower QIDS-C depression

264 depression scores were modestly better with sertraline treatment than with CBT.

265 (95% CI, 3.1-71.1; chi2 = 4.6; P = .03) for sertraline treatment vs placebo.

266 er the index ACS, nor an initial 6 months of sertraline treatment was associated with long-term morta

267 p to 225 mg/day of venlafaxine, or prolonged sertraline treatment with placebo (sertraline plus place

268 ent with sertraline, but by 60 minutes after sertraline treatment, brain accumulation of digoxin was

269 Intervention Twelve weeks of sertraline treatment, titrated by clinical response.

270 normative pattern in dMDD participants after sertraline treatment.

271 The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind,

272 Several antipsychotic drugs, such as sertraline, trifluoperazine, and fluphenazine, were foun

273 Sertraline, unlike venlafaxine, may turn out to be a tru

274 d protocol-driven, open-label treatment with sertraline, up to 200. mg/d over 10 weeks.

275 icular outflow tract obstruction and between sertraline use and ventricular septal defects.

276 m, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute tr

277 the antidepressants (citalopram, paroxetine, sertraline, venlafaxine, and bupropion, and their metabo

278 g pre- and post-ADM treatment (randomized to sertraline, venlafaxine-XR, or escitalopram).

279 with lower week-8 depression symptoms in the sertraline versus placebo arms.

280 (EMBARC) 8-week randomized clinical trial of sertraline versus placebo for major depressive disorder.

281 y region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Ra

282 f the clinical benefit of the antidepressant sertraline versus placebo.

283 manner both specific for the antidepressant sertraline (versus placebo) and generalizable across dif

284 or vomiting occurred more frequently in the sertraline vs placebo group (22.7% vs 10.4%, respectivel

285 time of randomization, the median dosage of sertraline was 150 mg/d (interquartile range [IQR], 150-

286 Sertraline was administered orally or via nasogastric tu

287 Treatment with olanzapine/sertraline was associated with higher remission rates du

288 n depth follow-up analyses demonstrated that sertraline was highly effective in alleviating abnormali

289 Sertraline was safe in patients with significant HF.

290 For escitalopram and sertraline, we observed higher rates of psychiatric hosp

291 nt plant where fluoxetine, atorvastatin, and sertraline were detected in fish bile at the downstream

292 Symptom responders to sertraline were distinguished by a decrease in NAc-insul

293 rval: -7.6 to -1.5; p = 0.034); exercise and sertraline were equally effective at reducing depressive

294 Null findings for sertraline were replicated in the stage 1 sample.

295 Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than dulo

296 n of extraction, basic drugs (citalopram and sertraline) were exhaustively extracted, whereas the rec

297 An exception was sertraline, which exhibited a kd value (0.4-0.5 d(-1)) t

298 hat heart failure (HF) patients treated with sertraline will have lower depression scores and fewer c

299 The final LeuBAT mutant binds the SSRI sertraline with a binding constant of 18 nM and displays

300 have shown that the clinical antidepressant sertraline (Zoloft) is biologically active in model syst